GLP-1 receptor agonist as a modulator of innate immunity

GLP-1 receptor agonist as a modulator of innate immunity

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid hormone secreted by L cells in the distal ileum, colon, and pancreatic α cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite...

Full description

Bibliographic Details
Main Authors:	Jun Chen, Aihua Mei, Yingying Wei, Chunlei Li, Hang Qian, Xinwen Min, Handong Yang, Lingli Dong, Xiaoquan Rao, Jixin Zhong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Immunology
Subjects:	glucagon-like peptide-1 liraglutide inflammatory diseases immunomodulation signal pathways
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.997578/full

Similar Items

Role of Incretin Axis in Inflammatory Bowel Disease
by: Lihua Duan, et al.
Published: (2017-12-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
by: Collin Vandemark, et al.
Published: (2023-02-01)

Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release
by: Michael P. Greenwood, et al.
Published: (2023-04-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
by: Shaomin Shi, et al.
Published: (2023-09-01)

GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
by: Laurence Aoun, et al.
Published: (2024-03-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Efficacy and Safety of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus Treatment: Systematic Review
by: Ana Paula Martins, et al.
Published: (2016-04-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

GLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes
by: Shivani Srivastava, et al.
Published: (2019-06-01)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019-08-01)

In Alzheimer’s Disease, Six-Month Treatment with GLP-1 Analogue Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
by: Michael eGejl, et al.
Published: (2016-05-01)

Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients
by: Huang J, et al.
Published: (2018-10-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin
by: Pin Chen, et al.
Published: (2021-10-01)

Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice
by: Yangzhao Zhou, et al.
Published: (2023-09-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022-12-01)

Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
by: Aleksandra Szczesnowicz, et al.
Published: (2023-09-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Liraglutide Accelerates Ischemia‐Induced Angiogenesis in a Murine Diabetic Model
by: Yu‐xin Zhu, et al.
Published: (2023-02-01)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
by: Yutaka Seino, et al.
Published: (2022-08-01)

Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
by: Bo Liang, et al.
Published: (2020-07-01)

GLP-2 regulation of intestinal lipid handling
by: Kundanika Mukherjee, et al.
Published: (2024-02-01)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
by: Eva W. Iepsen, et al.
Published: (2020-04-01)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
by: Lalita Prasad-Reddy, et al.
Published: (2015-07-01)

CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
by: Everton CAZZO, et al.
Published: (2016-12-01)

Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats
by: Vincent N. Marty, et al.
Published: (2020-12-01)

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
by: Ziqi Zhang, et al.
Published: (2023-07-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
by: Shinje Moon, et al.
Published: (2021-06-01)

Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway
by: Yanzhen Cheng, et al.
Published: (2022-05-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
by: Ziqi Zhang, et al.
Published: (2023-10-01)

Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
by: Kazuho Inoue, et al.
Published: (2022-05-01)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
by: Kosuke Sawami, et al.
Published: (2022-09-01)